A Phase 2/3 interventional study of Rasagiline in REM Sleep Behavior Disorder, Parkinson Disease and Synucleinopathies, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Withdrawn. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-07.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2/3, Interventional, and Treatment
To investigate whether a year of rasagiline may reduce the progression from idiopathic REM sleep behavior disorder (RBD) to Parkinson's disease (PD).
101 studies on the registry are indexed under REM Sleep Behavior Disorder; 45 are open to participants now.
Browse REM Sleep Behavior Disorder studies →Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,047 studies on the registry; 502 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
0-52 week: rasagiline 1 mg/day
Drug: Rasagiline
0-26 week: palcebo 1mg/day 27-52 week: rasagiline 1mg/day
Drug: Rasagiline
1 mg rasagiline
Disease-free survival time
Not diagnosed as any of the synucleinopathies (Parkinson's disease; dementia with lewy body; multiple system atrophy)
Time frame: 3 years after starting rasagiline treatment
Striatal dopaminergic innervation
Striatal binding ratio from DAT-Scan
Time frame: 0-3 years after starting rasagiline treatment
MDS-UPDRS-III
Time frame: 0-3 years after starting rasagiline treatment
MoCA
Time frame: 0-3 years after starting rasagiline treatment
MMSE
Time frame: 0-3 years after starting rasagiline treatment
HAMA
Time frame: 0-3 years after starting rasagiline treatment
HAMD
Time frame: 0-3 years after starting rasagiline treatment
RBDQ-HK
Time frame: 0-3 years after starting rasagiline treatment
PSQI
Time frame: 0-3 years after starting rasagiline treatment
PDQ39
Time frame: 0-3 years after starting rasagiline treatment
SCOPA-AUT
Time frame: 0-3 years after starting rasagiline treatment
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rasagiline
Second Affiliated Hospital, School of Medicine, Zhejiang University →